ENGN on Nasdaq

enGene Therapeutics Inc.

Biological products company, listed on Nasdaq (ENGN). Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerENGN on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersZ41
  • Incorporated inCanada (Federal Level)2
  • Business address4868 Rue Levy, Suite 220, Saint-Laurent2
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income345-$123.2M in 2025+534% since 2022
-$150.0M-$100.0M-$50.0M02022: -$19.4M-$19.4M20222023: -$26.1M-$26.1M2023+34%2024: -$62.3M-$62.3M2024+139%2025: -$123.2M-$123.2M2025+98%
Net income345-$117.3M in 2025+380% since 2022
-$150.0M-$100.0M-$50.0M02022: -$24.5M-$24.5M20222023: -$99.9M-$99.9M2023+308%2024: -$55.1M-$55.1M2024−45%2025: -$117.3M-$117.3M2025+113%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-10-312024-10-31
Research and development$94.5M$38.3M
General and administrative$28.7M$24.0M
Total operating expenses$123.2M$62.3M
Loss from operations$123.2M$62.3M
Interest income-$9.4M-$10.4M
Interest expense$3.0M$2.8M
Gain on extinguishment of debt$0$366.0K
Other expenses (income), net$569.0K$113.0K
Total other income, net-$5.9M-$7.1M
Net loss before income taxes$117.3M$55.2M
Provision for (recovery of) income taxes$0-$19.0K
Net loss$117.3M$55.1M
Unrealized (gain) loss on available-for-sale investments-$531.0K-$403.0K
Total comprehensive loss$116.8M$54.7M
Net loss per share of common shares, basic$2.29$1.46
Net loss per share of common shares, diluted$2.29$1.46
Weighted-average common shares outstanding, basic51.1M shares37.8M shares
Weighted-average common shares outstanding, diluted51.1M shares37.8M shares

Compare enGene Therapeutics Inc. with another company

Leadership

Who has led enGene Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jason David Hanson2023
  2. Ronald Harold Wilfred Cooper2024–now

President

  1. Ronald Harold Wilfred Cooper2025–now

Chief financial officer

  1. Alexandre Jean-Rene Erwan Grassin2023
  2. D. Ryan Daws2023–now

Chief operating officer

  1. Alexander Julian Nichols2023
2025
Board members and other officers (25)

Former names

  • enGene Holdings Inc.Jun 14, 2023 to Mar 9, 20262

Timeline

  1. Jul 24, 2024New chief executive Ronald Harold Wilfred Cooper becomes CEO8
  2. Oct 31, 2023New chief executive Jason David Hanson becomes CEO9

Filings

267 filings to the SEC since October 2021: 5 annual reports, 9 quarterly reports, 46 major events, 96 insider forms, 44 large holders, 67 other. The latest 20:

  1. Sep 24, 20264 EDGAR
  2. Sep 8, 202610-Q EDGAR
  3. Sep 8, 20268-K EDGAR
  4. Aug 14, 2026SCHEDULE 13G/A EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 13, 2026SCHEDULE 13G/A EDGAR
  8. Aug 12, 2026SCHEDULE 13G/A EDGAR
  9. Aug 11, 20268-K EDGAR
  10. Jul 22, 2026SCHEDULE 13G EDGAR
  11. Jul 22, 20263 EDGAR
  12. Jul 22, 20263 EDGAR
  13. Jul 17, 20268-K EDGAR
  14. Jul 16, 20268-K EDGAR
  15. Jun 18, 20268-K/A EDGAR
  16. Jun 17, 20264 EDGAR
  17. Jun 17, 20264 EDGAR
  18. Jun 17, 20264 EDGAR
  19. Jun 17, 20264 EDGAR
  20. Jun 17, 20264 EDGAR

The 267 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

17 open-market trades by officers, directors and large owners since October 2021: 14 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 22, 2026Grossman WilliamInterim Chief Medical OfficerBuy5,102$1.97$10.1KForm 4
Oct 30, 2024Forbion Growth Management B.V.10% ownerBuy561,797$8.90$5.0MForm 4
Oct 8, 2024Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy800$6.60$5.3KForm 4
Oct 7, 2024Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy11,844$6.55$77.6KForm 4
Oct 4, 2024Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy5,997$6.54$39.2KForm 4
Oct 3, 2024Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy5,769$6.48$37.4KForm 4
Oct 2, 2024Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy10,153$6.37$64.7KForm 4
Oct 1, 2024Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy35,279$6.44$227.2KForm 4
Sep 30, 2024Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy341,332$6.34$2.2MForm 4
Sep 27, 2024Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy41,639$5.97$248.8KForm 4
Sep 27, 2024Cooper Ronald Harold WilfredCEO & PresidentBuy10,000$5.70$57.0KForm 4
Apr 22, 2024FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC10% ownerSale47,854$15.00$717.8KForm 4
Apr 19, 2024FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC10% ownerSale100$15.00$1.5KForm 4
Apr 18, 2024FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC10% ownerSale4,575$15.01$68.7KForm 4
Dec 29, 2023Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy10,020$9.06$90.8KForm 4
Dec 28, 2023Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy5,050$7.69$38.8KForm 4
Dec 27, 2023Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy2,750$7.17$19.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 56. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BML Capital Management, LLC6,669,908$11.5M6.6%New
Siren, L.L.C.6,256,662$10.8M0.2%New
Perceptive Advisors LLC4,822,169$8.3M0.1%New
Ameriprise Financial Inc2,675,876$4.6M0.0%New
Nextech Invest Ltd.2,324,943$4.0M0.2%New
ADAR1 Capital Management, LLC2,104,986$3.6M0.2%New
Vestal Point Capital, LP1,667,430$2.9M0.1%New
Acorn Capital Advisors, LLC1,271,257$2.2M0.6%New
Peapod Lane Capital LLC1,102,149$1.9M1.3%New
Balyasny Asset Management L.P.1,007,344$1.7M0.0%New
Millennium Management LLC966,627$1.7M0.0%New
Renaissance Technologies LLC829,700$1.4M0.0%New
Citadel Advisors LLC717,686$1.2M0.0%New
Affinity Asset Advisors, LLC600,000$1.0M0.1%New
UBS Group AG509,087$880.7K0.0%New
Eversept Partners, LP469,584$812.4K0.0%New
Kynam Capital Management, LP457,855$792.1K0.0%New
Seven Fleet Capital Management LP411,065$711.1K0.1%New
Jane Street Group, LLC382,459$661.7K0.0%New
Rangeley Capital, LLC305,102$527.8K0.5%New
Barclays PLC282,515$488.8K0.0%New
Kennedy Capital Management LLC268,735$464.9K0.0%New
Woodline Partners LP250,000$432.5K0.0%New
Quadrature Capital Ltd239,035$413.5K0.0%New
Squarepoint Ops LLC215,381$372.6K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53